Roche: No new cost-cutting programs; Pfizer to build in Saudi Arabia;

> Roche chairman Franz Humer: "We don't need new [cost-cutting] programs but we will always pursue efficiency improvements." Story

> Pfizer ($PFE) follows Sanofi ($SNY) into Saudi Arabia, snagging a 65,000-square-meter tract in the King Abdullah Economic City for a manufacturing facility. Article

> A rise in OxyContin smuggling from Canada brings back to the U.S. the drug's earlier formulation, which lacks the more effective abuse deterrents of the one now in use. Story

> GlaxoSmithKline ($GSK) plans to invest $7 million in two production lines at a plant in Romania where it manufactures the antidepressant Seroxat and the HIV treatment Retrovir. Article

> China's drug regulator has begun inspections of overseas manufacturing plants. Article

> Controlled- and targeted-release specialist Intellipharmaceutics International says its Toronto oral solid dosage forms manufacturing facility has been dubbed "acceptable" following a cGMP and pre-approval inspection by the FDA. Intellipharmaceutics release

> Quebec-based IntelGenx ($IGXT) has won FDA approval for depression treatment CPI-300, a 450-mg formulation of the Wellbutrin XL API, bupropion hydrochloride. IntelGenx release

> Pfizer ($PFE) continues to push for the sale of two upstate New York plants, in Rouses Point and Chazy, in "an extremely challenging and slow marketplace." Story

> Modernized traditional Chinese medicine appears to be gaining in popularity: Bohai Pharmaceuticals ($BOPH) reports a 78% revenue leap to $30 million for the latest quarter. Bohai release